Resource Center
Explore Resource Types
We have housed the technical documents (SDS, COAs, Manuals and more) in a dedicated section.
Explore all All Resources
Filters
Select resource types
Select products & services
Select solutions (2)
Active Filters (2)
Clear All
157 - 168 of 173 Results
Sort by:
Best Match
Application Note
Biochemical binding ADCC assays utilizing AlphaLISA toolbox reagents for the characterization of hIgGs and FcγR1A
In this application note we demonstrate the ease with which AlphaLISA toolbox reagents can be used to develop any FcγR binding assay across the various stages of biologics research and development, including therapeutic screening and GMP Lot Release.
Literature - Publication Review
Current approaches to identify possible COVID-19 therapeutics
Current approaches to identify possible COVID-19 treatment strategies fall into one of three categories: Antivirals, antibodies, or protein-protein interaction inhibitors.
Whitepaper
Leveraging next-generation cell line development technologies for cost-effective biotherapeutic applications
Reviewing the transformative innovations within the cell line development process to help improve biotherapeutics.
Application Note
Development of pharmacokinetic (PK) assays for detecting biosimilars targeting TNF alpha using AlphaLISA
In this Application Note, AlphaLISA™ assays are used for detecting biosimilars targeting TNF alpha. Learn more.
Application Note
Antigen-stimulated PBMC cytokine release measured by AlphaLISA bovine cytokine kits
This application note demonstrates the performance of AlphaLISA bovine cytokine kits by measuring the cytokine release from antigenstimulated PBMCs isolated from cow blood and shows how cytokine measurements are critical for understanding cell mediated immune responses during vaccine development.
Application Note
Simultaneous detection of drug efficacy and toxicity by combining HTRF, AlphaLISA, or AlphaLISA SureFire Ultra with ATPlite
This application note demonstrates how compound’s mechanism of action and potential cytotoxic effects can be deciphered thanks to the combination of AlphaLISA™, HTRF™ or AlphaLISA™ SureFire® Ultra™ immunoassays with ATPlite™ 1step cell viability assay.
Application Note
Simultaneous measurement of chemokine/cytokine release and antibody-dependent cellular cytotoxicity upon binding with rituximab
Simultaneous detection of ADCC activity and release of chemokines and cytokines from activated NK cells is possible via the combined use of DELFIA TRF and AlphaLISA technologies.
Application Note
A fast and simple chemiluminescent assay for monitoring of DNA-protein interactions
In this application note, we use HepG2 nuclear extracts to demonstrate the binding of Sp1 and HNF1 transcription factors to tagged oligonucleotides containing required cognate response elements. Read this note to see the results and access detailed data compared to EMSA.
Application Note
Evaluating the specificity of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits
Find out how the AlphaLISA human/mouse PD-1/PD-L1 binding assays provide a fast, powerful, homogeneous platform for obtain binding potencies from potential novel drug candidates.
Application Note
Utilization of AlphaLISA technology to accurately detect asthma biomarkers in human serum
In this application note, AlphaLISA technology was used to quantify biomarker levels in serum samples, specifically Human IL-21, IL-33, and TNFα.
Application Note
Fc-Receptor binding ADCC assays utilizing AlphaLISA technology: Characterization of hIgGs and FcγRIIIa
This application note demonstrates how AlphaLISA assay can be used to determine the binding activity of human IgG Fc fragment to human FcγRIIIa and to study how other antibodies bind to FcγRIIIa.
Application Note
No-Wash IP1 assays are a powerful readout to characterize compounds modulating the FGFR signaling pathway in cancer drug research
This application note demonstrates that detecting the intracellular accumulation of IP1, mediated by FGFR-dependent activation of PLCγ1, can be a powerful alternative for characterizing compounds that modulate FGFR signaling in various cancer cell lines expressing FGFR1, FGFR2, and FGFR3.
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.